Email address
[email protected]Contact number
81-3-6775-1067Share profile
Band 3
Provided by Hiroshi Ishihara
Hiroshi Ishihara specializes in the healthcare and life sciences industry. He handles many commercial transactions, such as M&A of pharmaceutical companies and license agreements, and has extensive experience in international and domestic M&A transactions. He also advises clients on regulations relating to drugs, medical devices, and regenerative medicine.
Admitted in Japan (2000); Admitted in California (2006); Admitted in New York (2007); Visiting Attorney at Kirkland & Ellis LLP (2005 - 2006); Seconded to the Bank of Japan and a general trading company in Japan
Dai-ichi Tokyo Bar Association (Japan), 2000; State Bar of California (USA), 2006; New York State Bar Association (USA), 2007; Advisor to the Medical Affairs Study Group of the Japan Pharmaceutical Industry Legal Affairs Association (Japan)
“Digital Healthcare 2023 – Japan” (Chambers Global Practice Guide, 2023); “Amendment to Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices” (LexisNexis 2022); “Legal Matters regarding Life Sciences and Health Care - Navigation regarding Regulations, Intellectual Properties and Corporate Matters (Second Edition)” (Shoji-homu 2020)
University of Tokyo (Bachelor of Economics, 1997); Keio University (LLB, 2004); Columbia University School of Law (LLM, 2005)
Provided by Chambers
Hiroshi Ishihara is a co-head of Anderson Mori's healthcare, pharmaceutical and life sciences department, and he routinely advises clients on regulatory issues and handles commercial transactions, such as licence agreements.
Provided by Chambers
Hiroshi is active advising on mergers and acquisitions and joint venture projects in the life science industry.
In addition to his broad perspective and high problem-solving skills, he always does his best to find the best solution by collaborating with suitable lawyers from both domestic and global offices.
Hiroshi is active advising on mergers and acquisitions and joint venture projects in the life science industry.
In addition to his broad perspective and high problem-solving skills, he always does his best to find the best solution by collaborating with suitable lawyers from both domestic and global offices.
